Pearson E R, Velho G, Clark P, Stride A, Shepherd M, Frayling T M, Bulman M P, Ellard S, Froguel P, Hattersley A T
Department of Vascular Medicine and Diabetes Research, School of Postgraduate Medicine and Health Sciences, University of Exeter, Devon, UK.
Diabetes. 2001 Feb;50 Suppl 1:S101-7. doi: 10.2337/diabetes.50.2007.s101.
Mutations in the beta-cell genes encoding the glycolytic enzyme glucokinase (GCK) and the transcription factor hepatocyte nuclear factor (HNF)-1alpha are the most common causes of maturity-onset diabetes of the young (MODY). Studying patients with mutations in these genes gives insights into the functions of these two critical beta-cell genes in humans. We studied 178 U.K. and French MODY family members, including 45 GCK mutation carriers and 40 HNF-1alpha mutation carriers. Homeostasis model assessment of fasting insulin and glucose showed reduced beta-cell function in both GCK (48% controls, P<0.0001) and HNF-1alpha (42% controls, P<0.0001). Insulin sensitivity was similar to that of control subjects in the GCK subjects (93% controls, P = 0.78) but increased in the HNF-1alpha subjects (134.5% controls, P = 0.005). The GCK patients showed a similar phenotype between and within families with mild lifelong fasting hyperglycemia (fasting plasma glucose [FPG] 5.5-9.2 mmol/l, interquartile [IQ] range 6.6-7.4), which declined slightly with age (0.017 mmol/l per year) and rarely required pharmacological treatment (17% oral hypoglycemic agents, 4% insulin). HNF-1alpha patients showed far greater variation in fasting glucose both between and within families (FPG 4.1-18.5 mmol/l, IQ range 5.45-10.4), with a marked deterioration with age (0.06 mmol/l per year), and 59% of patients required treatment with tablets or insulin. Proinsulin-to-insulin ratios are increased in HNF-1alpha subjects (29.5%) but not in GCK (18.5%) subjects. In an oral glucose tolerance test, the 0- to 120-min glucose increment was small in GCK patients (2.4+/-1.8 mmol/l) but large in HNF-1alpha patients (8.5+/-3.0 mmol/l, P< 0.0001). This comparison shows that the clear clinical differences in these two genetic subgroups of diabetes reflect the quantitative and qualitative differences in beta-cell dysfunction. The defect in GCK is a stable defect of glucose sensing, whereas the HNF-1alpha mutation causes a progressive defect that alters beta-cell insulin secretion directly rather than the sensing of glucose.
编码糖酵解酶葡萄糖激酶(GCK)和转录因子肝细胞核因子(HNF)-1α的β细胞基因突变是青年发病的成年型糖尿病(MODY)最常见的病因。对这些基因突变患者的研究有助于深入了解这两个关键β细胞基因在人体中的功能。我们研究了178名英国和法国的MODY家族成员,其中包括45名GCK突变携带者和40名HNF-1α突变携带者。空腹胰岛素和葡萄糖的稳态模型评估显示,GCK突变携带者(为对照组的48%,P<0.0001)和HNF-1α突变携带者(为对照组的42%,P<0.0001)的β细胞功能均降低。GCK突变携带者的胰岛素敏感性与对照组相似(为对照组的93%,P = 0.78),但HNF-1α突变携带者的胰岛素敏感性增加(为对照组的134.5%,P = 0.005)。GCK患者在家族间和家族内表现出相似的表型,即终生轻度空腹高血糖(空腹血糖[FPG]5.5 - 9.2 mmol/L,四分位间距[IQ]范围6.6 - 7.4),且随年龄略有下降(每年0.017 mmol/L),很少需要药物治疗(17%使用口服降糖药,4%使用胰岛素)。HNF-1α患者在家族间和家族内的空腹血糖差异更大(FPG 4.1 - 18.5 mmol/L,IQ范围5.45 - 10.4),且随年龄显著恶化(每年0.06 mmol/L),59%的患者需要使用片剂或胰岛素治疗。HNF-1α突变携带者的胰岛素原与胰岛素比值升高(29.5%),而GCK突变携带者则未升高(18.5%)。在口服葡萄糖耐量试验中,GCK患者0至120分钟的血糖增加值较小(2.4±1.8 mmol/L),但HNF-1α患者较大(8.5±3.0 mmol/L,P<0.0001)。这种比较表明,这两个糖尿病遗传亚组明显的临床差异反映了β细胞功能障碍在数量和质量上的差异。GCK缺陷是葡萄糖感知的稳定缺陷,而HNF-1α突变导致的缺陷是渐进性的,它直接改变β细胞胰岛素分泌,而非葡萄糖感知。